A Exploratory Study of Apatinib Adjuvant Therapy for Hepatocellular Carcinoma With Portal Vein Invasion Who Underwent Radical Resection
Latest Information Update: 22 Apr 2020
At a glance
- Drugs Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 22 Apr 2020 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Aug 2017).
- 25 Jan 2020 Results assessing effect of postoperative apatinib treatment after resection of hepatocellular carcinoma with portal vein invasion, presented at the 2020 Gastrointestinal Cancers Symposium
- 29 Aug 2017 New trial record